Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-Week results of the VICTOR-El phase 2 trial

Journal of Infectious Diseases

Volumn 201, Issue 4, 2010, Pages 590-599

  Suleiman, Jamal ^a   Zingman, Barry S ^d   Diaz, Ricardo Sobhie ^b   Madruga, Jose Valdez Ramalho ^c   Dejesus, Edwin ^e   Slim, Jihad ^f   Mak, Carmen ^g   Lee, Erin ^g   McCarthy, Michael C ^g   Dunkle, M ^g   Walmsley, Sharon ^h  

^a Brasilmed Assistência Médica e Pesquisas ^*  (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Centro de Referencia e Treinamento em DST AIDS   (Brazil)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e ORLANDO IMMUNOLOGY CENTER   (United States)

^f ST MICHAEL S MEDICAL CENTER   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ENFUVIRTIDE; PLACEBO; RITONAVIR; VICRIVIROC; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOPULMONARY INSUFFICIENCY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLATULENCE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INFLUENZA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MILIARY TUBERCULOSIS; MULTIPLE ORGAN FAILURE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; RNA VIRUS; SIDE EFFECT; SINUSITIS; TINEA PEDIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS PNEUMONIA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 75749126915     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650342     Document Type: Article

References (16)

1. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007;21:685-692. (Pubitemid 46568625)
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 3 November 2008; 1-139. Available at; http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 10 December 2008.
3. Hanna GJ, Caliendo AM. Testing for HIV-1 drug resistance. Mol Diagn 2001; 6:253-263.
4. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV N Engl J Med 2002; 347:385-394.
5. Chen RY, Westfall AO, Mugavero MJ, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003;37:714-722. (Pubitemid 37100815)
6. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-1441.
7. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatmentexperienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007;196:304-312. (Pubitemid 47047471)
8. Phillips AN, King M. Assessing the impact of different virologic response definitions on response rates [abstract 7.3/3]. In: Program and abstracts of the 9th European AIDS Conference, Warsaw, Poland, 26-29 October 2003.
9. US Food and Drug Administration. Guidance for industry: antiretroviral drugs using plasma HIV RNA levels-clinical considerations for accelerated and traditional approval. October 2002. Available at: http://www.fda.gov/Cder/ guidance/3647fnl.htm. Accessed 21 October 2008.
10. Wilcox CM, Saag MS. Gastrointestinal complications of HIV infection: changing priorities in the HAART era. Gut 2008;57:861-870.
11. Walmsley S. Protease inhibitor-based regimens for HIV therapy: safety and efficacy. J Acquir Immune Defic Syndr 2007;45:S5-S13. (Pubitemid 46828214)
12. FauciAS.Multifactorialnatureofhumanimmunodeficiencyvirusdisease: implicationsfortherapy.Science1993;262:1011-1018.(Pubitemid24035036)
13. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296:815-826. (Pubitemid 44223105)
14. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909-4920.
15. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194:926-930. (Pubitemid 44454078)
16. Su Z, Reeves JD, Krambrink A, et al. Response to vicriviroc in HIV-infected treatment-experienced subjects using an enhanced version of the Trofile HIV co-receptor tropism assay: reanalysis of ACTG 5211 results [abstract H-895]. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Disease Society of America Annual Meeting (Washington, DC). Washington, DC: American Society for Microbiology/Infectious Disease Society of America, 2008:48/46.